PDCD1 and cancer: Our future work will focus on the impact of anti‐PD‐1 in vivo in people with HIV on ART without cancer and potential combinations of anti‐PD‐1 with other interventions, including therapeutic vaccines or antibodies and less toxic immune checkpoint blockers.